Capital International Sarl Neurocrine Biosciences Inc Transaction History

Capital International Sarl

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $782,350 - $1.07 Million	-8,934 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $387,428 - $544,519	-4,029 Reduced 31.08%	8,934 $859,000
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $71,645 - $109,763	842 Added 6.95%	12,963 $1.58 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $899,742 - $1.36 Million	-11,979 Reduced 49.71%	12,121 $1.05 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $2.02 Million - $2.45 Million	24,100 New	24,100 $2.17 Million

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Capital International Sarl, based on Form 13F filings with the SEC.

Stay updated on Capital International Sarl with notifications on news.